Phase 2aData readout

GH001 (inhalable mebufotenin) (5-MeO-DMT)

Bipolar depression

GHRSGH Research

Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset: GH001 (inhalable mebufotenin) (5-MeO-DMT)
Development stage: Phase 2a
Event type: Data readout
Indication: Bipolar depression

Research summary

What is being tracked?

This catalyst tracks a Phase 2a data readout for GH001 (inhalable mebufotenin) (5-MeO-DMT) in Bipolar depression. The expected timing is based on the latest available company guidance and may change.

Development notes

08/06/26:- Posters accepted for ISBD September 2026 and ECNP October 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source